Sofinnova Partners, a European life sciences venture capital firm, has completed the final close of Sofinnova Crossover II at €725 million, equivalent to approximately $815 million. The fund exceeded its original fundraising target and will invest primarily in European clinical-stage biotechnology and medical technology companies preparing for later-stage development, global expansion, and commercialization.
The new vehicle is expected to support approximately 15 companies over its investment period.
While its primary focus will be Europe, the fund will also pursue selected opportunities in the United States and other international markets.
Sofinnova believes the successful fundraising reflects increasing investor confidence in European life sciences businesses developing technologies with global commercial potential.
The fund will provide capital to companies approaching important stages of clinical development and business growth.
Supporting Clinical Development And Commercialization
Life sciences companies frequently require substantial financing to advance experimental therapies and medical technologies through clinical testing, regulatory approval, and commercialization.
Sofinnova Crossover II is designed to support businesses during these later stages of development.
Its investment strategy focuses on companies with promising scientific foundations, clinical validation, and leadership teams capable of expanding internationally.
Sofinnova believes the European market is producing an increasing number of competitive healthcare companies that need access to substantial growth capital.
The firm’s investment approach combines financial backing with industry expertise and strategic support.
Building On Crossover I
Sofinnova’s first crossover fund invested in several companies that subsequently completed significant corporate transactions or public market milestones.
These include LimFlow, acquired by Inari Medical; Calliditas Therapeutics, acquired by Asahi Kasei; and Amolyt Pharma, acquired by AstraZeneca.
The portfolio also included Abivax, which achieved a Nasdaq listing.
These investments demonstrate the firm’s strategy of backing life sciences companies as they advance toward larger commercial markets.
Crossover II has already invested in Hemab Therapeutics, CellCentric, and Neurent Medical.
The fund will continue seeking opportunities among biotechnology and medical technology companies with differentiated products and clinical development programs.
Investment Leadership And Institutional Support
The Crossover II strategy is led by Sofinnova partners Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat, and David Evans.
The fund is supported by the European Tech Champions Initiative, a fund-of-funds managed by the European Investment Fund.
Sofinnova Partners was founded in 1972 and operates from Paris, London, and Milan.
The firm has invested in more than 500 companies across its history and currently manages more than €4 billion in assets.
Its investment activities span life sciences and sustainability, from early-stage company formation through later-stage development.
The new €725 million fund strengthens Sofinnova’s capacity to support European life sciences companies seeking to compete internationally.
KEY QUOTES:
“The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believe they should have access to investors that can support them through the critical stages of growth and commercialization.”
Antoine Papiernik, Chairman And Managing Partner Of Sofinnova Partners
“We continue to see exceptional opportunities emerging across European life sciences. Many companies now have scientific strength, clinical validation, and leadership teams needed to compete on a global stage. With Sofinnova Crossover II, we are well positioned to support that next generation of leaders while maintaining the disciplined investment approach that defined our first fund.”
Kinam Hong, Partner At Sofinnova Partners

